Clinical Trial Results:
MULTICENTRE STUDY TO ASSESS CHANGES IN BONE MINERAL DENSITY OF THE SWITCH FROM TENOFOVIR TO ABACAVIR IN HIV-1-INFECTED SUBJECTS WITH LOSS OF BONE MINERAL DENSITY.
Summary
|
|
EudraCT number |
2010-019879-29 |
Trial protocol |
ES |
Global end of trial date |
06 Jul 2012
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
26 Jan 2018
|
First version publication date |
26 Jan 2018
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
OSTEOTENOFOVIR
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01153217 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Fundació Lluita contra la SIDA
|
||
Sponsor organisation address |
Crta de Canyet s/n, Badalona, Spain, 08916
|
||
Public contact |
CRA, Fundació Lluita contra la SIDA, +34 93 497 84 14, rescrig@flsida.org
|
||
Scientific contact |
CRA, Fundació Lluita contra la SIDA, +34 93 497 84 14,
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
06 Jul 2012
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
06 Jul 2012
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
06 Jul 2012
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate changes in BMD after the switch from tenofovir to abacavir in HIV-infected patients with low bone mineral density.
|
||
Protection of trial subjects |
not specific
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
07 Jul 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Spain: 54
|
||
Worldwide total number of subjects |
54
|
||
EEA total number of subjects |
54
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
54
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||
Recruitment
|
|||||||||||||||||||
Recruitment details |
The inclusion criteria were virological suppression during a tenofovircontaining regimen for more than 48 weeks and meeting the criteria for osteopenia/osteoporosis by DXA scan, according to the WHO classification. | ||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||
Screening details |
Fifty-four patients were enrolled in this clinical trial | ||||||||||||||||||
Period 1
|
|||||||||||||||||||
Period 1 title |
overall (overall period)
|
||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||
Blinding used |
Not blinded | ||||||||||||||||||
Arms
|
|||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||
Arm title
|
Abacavir group | ||||||||||||||||||
Arm description |
Abacavir 600mg + Lamivudine 300 mg every 24 hours + 1 PI or 1 NNRTI or raltegravir | ||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||
Investigational medicinal product name |
Kivexa
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Abacavir 600mg + Lamivudine 300mg every 24 hours
|
||||||||||||||||||
Arm title
|
Tenofovir group | ||||||||||||||||||
Arm description |
Tenofovir 300 mg + Emtricitabine 200 mg or Lamivudine 300 mg every 24 hours + 1 PI or 1 NNRTI or raltegravir | ||||||||||||||||||
Arm type |
Active comparator | ||||||||||||||||||
Investigational medicinal product name |
Truvada, Atripla, Virad+Emtriva, Virad+Epivir
|
||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||
Other name |
|||||||||||||||||||
Pharmaceutical forms |
Film-coated tablet
|
||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||
Dosage and administration details |
Tenofovir 245mg + Emtricitabine 200mg or Lamivudine 300mg every 24h
|
||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Abacavir group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Abacavir 600mg + Lamivudine 300 mg every 24 hours + 1 PI or 1 NNRTI or raltegravir | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Tenofovir group
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Tenofovir 300 mg + Emtricitabine 200 mg or Lamivudine 300 mg every 24 hours + 1 PI or 1 NNRTI or raltegravir | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Abacavir group
|
||
Reporting group description |
Abacavir 600mg + Lamivudine 300 mg every 24 hours + 1 PI or 1 NNRTI or raltegravir | ||
Reporting group title |
Tenofovir group
|
||
Reporting group description |
Tenofovir 300 mg + Emtricitabine 200 mg or Lamivudine 300 mg every 24 hours + 1 PI or 1 NNRTI or raltegravir |
|
||||||||||||||||
End point title |
changes in increase BMD scores: femoral BMD | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
from baseline at week 48
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
comparing percentage of change between groups | |||||||||||||||
Comparison groups |
Abacavir group v Tenofovir group
|
|||||||||||||||
Number of subjects included in analysis |
54
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
equivalence | |||||||||||||||
P-value |
= 0.229 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Confidence interval |
|
||||||||||||||||
End point title |
changes in increase BMD scores: lumbar spine BMD | |||||||||||||||
End point description |
||||||||||||||||
End point type |
Primary
|
|||||||||||||||
End point timeframe |
from baseline at week 48
|
|||||||||||||||
|
||||||||||||||||
Statistical analysis title |
comparing percentage of change between groups | |||||||||||||||
Comparison groups |
Abacavir group v Tenofovir group
|
|||||||||||||||
Number of subjects included in analysis |
54
|
|||||||||||||||
Analysis specification |
Pre-specified
|
|||||||||||||||
Analysis type |
equivalence | |||||||||||||||
P-value |
= 0.312 | |||||||||||||||
Method |
t-test, 2-sided | |||||||||||||||
Confidence interval |
|
|||||||||||||
End point title |
patients who experienced virological failure and grade 3–4 toxicity | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
week 48
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
from baseline to week 48
|
|||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Non-systematic | |||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
DAIDS AE GRADING TAB | |||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
1.0
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
abacavir group
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
tenofovir group
|
|||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 1% | ||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |